Valeant Pharmaceuticals International, Inc. Agrees To Acquire Obagi Medical Products, Inc. For $19.75 Per Share In Cash
Obagi Medical Products, Inc (NASDAQ: OMPI) (the “Company” or “Obagi”) today announced that it entered into a definitive merger agreement with Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) under which Valeant will acquire all of the outstanding common stock of Obagi for $19.75 per share in cash. The transaction, which values Obagi common stock at approximately $360 million, was unanimously approved by the Obagi Board of Directors. The $19.75 per share price represents a 42% premium to Obagi’s closing share price on Thursday, March 14, 2013, the last trading day prior to the disclosure of its fourth quarter and full year 2012 earnings, and a 40% premium to the thirty day prior stock price.
Albert Hummel, Obagi’s President and Chief Executive Officer said, “Our Board of Directors has determined that this all cash offer is in the best interest of our stockholders and validates both the hard work from our employees and our brand’s unique leadership position within the market. We look forward to being part of the Valeant family of companies.”
Under the terms of the merger agreement, Valeant will commence a tender offer for all of the outstanding shares of common stock of Obagi. The Obagi Board of Directors recommends that Obagi stockholders tender their shares in accordance with the terms of the merger agreement.
Both parties expect the transaction to be completed in the second quarter 2013, subject to customary terms and conditions, including the tender of a majority of Obagi’s outstanding shares of common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The merger agreement provides for the parties to effect a merger following the completion of the tender offer, which will result in all shares of common stock not tendered in the tender offer being converted into the right to receive $19.75 per share in cash.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV